Clinical Trials

1,514 enrolled

Triple Negative Breast Neoplasms

NCT07413939 2026-06-10

BREnnA

Phase 2/3 Recruiting

650 enrolled

HER2-positive Breast Cancer

NCT06312176 2026-06-08

MK-2870-010

1,200 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT06393374 2026-06-08

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

1,530 enrolled

Triple Negative Breast Neoplasms

NCT06901531 2026-06-05

LUCERNA

500 enrolled

Tumor-Agnostic

Adenocarcinoma, Neoplasms

NCT07007559 2026-06-05

ASPEN-09-03

120 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT03899155 2026-06-03

Pan Tumor Rollover Study

Phase 3 Active not recruiting

1,500 enrolled

Tumor-Agnostic

Neoplasms

NCT05568095 2026-06-02

STAR-221

1,040 enrolled

Phase 3 Active not recruiting

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT06018337 2026-06-02

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

541 enrolled

Breast Neoplasms

NCT06875128 2026-06-01

DELUMA

90 enrolled

Breast Neoplasms

NCT06966700 2026-06-01

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

2,400 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07060807 2026-06-01

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

1,000 enrolled

Breast Neoplasms

NCT06926868 2026-05-29

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Phase 2/3 Recruiting

500 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05365581 2026-05-28

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Phase 1 Recruiting

398 enrolled

Tumor-Agnostic

Adenocarcinoma

NCT07024615 2026-05-28

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

Phase 1 Recruiting

25 enrolled

Pancreatic Ductal Adenocarcinoma

NCT06247995 2026-05-27

NeoB-Cap1

Phase 1/2 Recruiting

58 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07431281 2026-05-27

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

2,130 enrolled

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT06324357 2026-05-26

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Phase 1/2 Recruiting

768 enrolled

BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

NCT06469944 2026-05-26

MK-3475-06C

Phase 1/2 Recruiting

160 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT07461454 2026-05-26

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

376 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07606599 2026-05-26

A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure

398 enrolled

Biliary Tract Neoplasms

NCT05464030 2026-05-22

Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)

Phase 1 Recruiting

200 enrolled

Phase 3 Not yet recruiting

Colorectal Neoplasms

NCT07582315 2026-05-22

A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy and PD-1/PD-L1 Monoclonal Antibody Therapy(PANKU-BTC01)

538 enrolled

Biliary Tract Neoplasms

NCT06797635 2026-05-20

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

372 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT05152147 2026-05-19

HERIZON-GEA-01

920 enrolled

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

NCT07069712 2026-05-18

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

100 enrolled

Stomach Neoplasms

NCT07331155 2026-05-18

A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]